BofA raised the firm’s price target on SpringWorks Therapeutics (SWTX) to $87 from $65 and keeps a Buy rating on the shares. Shares gained a “significant boost” after the company received approval for one of its lead assets, Gomekli, notes the analyst, who thinks Gomekli can gain significant market share due to approval across age ranges and formulation as an oral solution.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SWTX:
- SpringWorks Therapeutics CEO sells $2.56M in common stock
- Biotech Alert: Searches spiking for these stocks today
- Wedbush ups SpringWorks target to $81, expects Merck KGaA ‘official’ offer soon
- SpringWorks sets wholesale acquisition cost for Gomekli at $206.25 per mg
- SpringWorks Therapeutics sets wholesale acquisition cost for GOMEKLI at $206.25